Go Pro

Nuvectis Pharma (NVCT) Stock Forecast & Price Target

Nuvectis Pharma logo
$25.89 +2.02 (+8.46%)
Closing price 08/25/2026 04:00 PM Eastern
Extended Trading
$25.89 +0.00 (+0.00%)
As of 04:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Nuvectis Pharma - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
1
Hold
0
Buy
3

Based on 4 Wall Street analysts who have issued ratings for Nuvectis Pharma in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 4 analysts, 1 has given a sell rating, and 3 have given a buy rating for NVCT.

Consensus Price Target

$35.00
35.19% Upside
According to the 4 analysts' twelve-month price targets for Nuvectis Pharma, the average price target is $35.00. The highest price target for NVCT is $39.00, while the lowest price target for NVCT is $33.00. The average price target represents a forecasted upside of 35.19% from the current price of $25.89.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for NVCT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Nuvectis Pharma and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NVCT Analyst Ratings Over Time

TypeCurrent Forecast
8/26/25 to 8/26/26
1 Month Ago
7/27/25 to 7/27/26
3 Months Ago
5/28/25 to 5/28/26
1 Year Ago
8/26/24 to 8/26/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
2 Buy rating(s)
1 Buy rating(s)
3 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$35.00$35.00$10.00$15.33
Forecasted Upside35.19% Upside79.12% Upside-1.86% Downside123.84% Upside
Consensus RatingModerate BuyHoldHoldBuy

NVCT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NVCT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Nuvectis Pharma Stock vs. The Competition

TypeNuvectis PharmaHealthcare CompaniesBroader Market
Consensus Rating Score
2.50
2.30
2.53
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside35.19% Upside903.93% Upside12.47% Upside
News Sentiment Rating
Positive News

See Recent NVCT News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
8/24/2026
Cantor Fitzgerald logo
Cantor Fitzgerald
5 of 5 stars
Initiated CoverageOverweight
8/20/2026
Weiss Ratings logo
Weiss Ratings
5 of 5 stars
 UpgradeSell (E+)Sell (D-)
7/6/2026
UBS Group AG logo
UBS Group
4 of 5 stars
 Set Target$33.00+68.63%
7/6/2026Boost TargetBuy$20.00 ➝ $33.00+68.63%
6/22/2026Boost TargetBuy$13.00 ➝ $39.00+182.57%
4/2/2025Initiated CoverageBuy$17.00+81.82%
3/17/2025Initiated CoverageBuy$19.00+114.69%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 07:06 AM ET.


NVCT Forecast - Frequently Asked Questions

According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for Nuvectis Pharma is $35.00, with a high forecast of $39.00 and a low forecast of $33.00.

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nuvectis Pharma in the last year. There is currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NVCT shares.

According to analysts, Nuvectis Pharma's stock has a predicted upside of 35.19% based on their 12-month stock forecasts.

Over the previous 90 days, Nuvectis Pharma's stock had 1 upgrade and 1 downgrade by analysts.

Nuvectis Pharma has been rated by research analysts at Cantor Fitzgerald, HC Wainwright, Roth Capital, UBS Group, and Weiss Ratings in the past 90 days.

Analysts like Nuvectis Pharma more than other "healthcare" companies. The consensus rating for Nuvectis Pharma is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how NVCT compares to other companies.


MarketBeat monitors more than a dozen sources for Nuvectis Pharma analyst ratings, with the most recent rating issued on 8/24/2026.
From Our Partners